Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics Hires Former Venture Capitalist as CEO

NEW YORK, June 22 - Rubicon Genomics has appointed Thomas Collet, a former health care venture capitalist, to lead the company as president and chief executive officer, the company said Friday. 

Collet joined Rubicon, an Ann Arbor, Mich.-based developer of DNA amplification technology, from Tullis-Dickerson, a healthcare venture fund in Ann Arbor where he was general partner. Prior to that, Collet served as vice president for business development at Integrated Protein Technologies, a unit of Monsanto. Collet also worked as a consultant to pharmaceutical and healthcare companies at McKinsey.

Rubicon specializes in developing alternatives to PCR for amplifying DNA sequences and identifying SNPs. The company's technology, called OmniPlex, involves reformatting chromosomes into new molecules called plexisomes that are more easily amplified and manipulated, the company said in a statement. The technology may ultimately have applications in personalized medicine, the company said.

The company also said Friday that the US Patent and Trademark Office had issued a patent on the company's OmniPlex technology.

"Thomas joins us at the perfect time in Rubicon's evolution as we have just established proof-of-principle for our OmniPlex technology, and are poised to commercialize our technology on an accelerated growth path," Richard Sloan, the company's director, said in a statement.

Rubicon was formed in 1998 by researchers at the University of Michigan and the Engelhardt Insitute of Molecular Biology in Moscow.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.